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The cyclin-dependent kinase (CDK)-inhibitor 1C (CDKN1C) gene is expressed
from the maternal allele and is located within the centromeric imprinted domain
at chromosome 11p15. It is a negative regulator of proliferation, with loss-of-
function mutations associated with the overgrowth disorder Beckwith–Wiedemann
syndrome. Recently, gain-of-function mutations within the PCNA domain have been
described in two disorders characterized by growth failure, namely IMAGe (intra-
uterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita and
genital abnormalities) syndrome and Silver–Russell syndrome (SRS). Over-expression
of CDKN1C by maternally inherited microduplications also results in SRS, suggesting
that in addition to activating mutations this gene may regulate growth by changes in
dosage. To determine if CDKN1C is involved in non-syndromic IUGR we compared
the expression and DNA methylation levels in a large cohort of placental biopsies from
IUGR and uneventful pregnancies. We observe higher levels of expression of CDKN1C
in IUGR placentas compared to those of controls. All placenta biopsies heterozygous
for the PAPA repeat sequence in exon 2 showed appropriate monoallelic expression
and no mutations in the PCNA domain were observed. The expression profile was
independent of both genetic or methylation variation in the minimal CDKN1C promoter
interval and of methylation of the cis-acting maternally methylated region associated with
the neighboring KCNQ1OT1 non-coding RNA. Chromatin immunoprecipitation revealed
binding sites for CTCF within the unmethylated CDKN1C gene body CpG island and
putative enhancer regions, associated with the canonical enhancer histone signature,
H3K4me1 and H3K27ac, located ∼58 and 360 kb away. Using 3C-PCR we identify
constitutive higher-order chromatin loops that occur between one of these putative
enhancer regions and CDKN1C in human placenta tissues, which we propose facilitates
expression.
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INTRODUCTION
Intrauterine growth restriction (IUGR) is a condition in which
a fetus is unable to achieve its genetically determined in utero
size and is associated with increased risk of perinatal morbidity
and mortality. The mechanisms that lead to IUGR are not
completely understood. Etiologically, restricted growth can be
of fetal, maternal and placental origin. Aberrant maternal-fetal
circulation has been consistently implicated because of the
observed abnormalities in Doppler dynamics of the uterine and
umbilical arteries, which indicate increased resistance in the
maternal spiral arteries and the placental circulation, respectively
(Society for Maternal-Fetal Medicine Publications Committee
et al., 2012). Pregnancies that are complicated by IUGR often
require early elective delivery due to higher risk of fetal distress,
resulting in additional complications associated with prematurity
(Miller et al., 2009) which require prolonged admission in
neonatal intensive care.
Chromosomal abnormalities are often a cause of severe
growth restriction (Romero et al., 2015). With the advent of
genome-wide technologies, altered gene expression profiles in
the fetus or placenta are commonly being described in IUGR
and other pregnancy complications. These abnormal expression
profiles are often associated with increased epigenetic variance,
suggesting links between underlying chromatin dynamics and
fetal growth. In particular, imprinted genes, of which there are
∼150 described in the human genome, have been shown to
be essential for appropriate fetal and placenta development.
Emerging evidence implicates aberrant expression levels of
imprinted genes in not only classical imprinting disorders
(reviewed in Eggermann et al., 2015), but also in many common
multifactorial human diseases, which include complications of
pregnancy such as IUGR, pre-eclampsia (reviewed in Monk,
2015) and postnatal disorders including obesity and type 2
diabetes (Kong et al., 2009).
Genomic Imprinting
Imprinted genes encode products implicated in diverse
physiological processes, many of them playing a role in growth
and development. The molecular mechanisms regulating
genomic imprinting involve the establishment of parent-specific
epigenetic modifications in the germline, which result in
monoallelic expression of transcripts in a parent-of-origin
dependent manner (Ferguson-Smith, 2011). Until recently,
it was thought that imprinted genes have a tendency to
cluster together as a result of sharing cis-regulatory elements,
including differentially methylated regions (DMRs) that inherit
methylation from one of the two gametes. However, recent
genome-wide screens for novel imprinted loci have identified
placenta-specific maternally methylated DMRs that are more
prevalent in the human genome than ubiquitous imprinted
domains (Court et al., 2014b), and that do not orchestrate
imprinting of neighboring genes (Sanchez-Delgado et al., 2015).
The KCNQ1OT1 Imprinted Domain
Distal mouse chromosome 7 harbors the largest known
imprinted cluster and is highly conserved in humans. Two
germline DMRs control different sets of imprinted transcripts
within this >1 Mb cluster, divided into two functionally
independent domains. The centromeric domain is controlled by
the paternally methylated H19/IGF2:IG-DMR (note adoption of
recommended DMR name as recommended by the European
Network for Human Congenital Imprinting Disorders –
EUCID.net1. Also known as the H19 ICR or ICR1; Thorvaldsen
et al., 1998), whereas the telomeric domain is regulated by
the KCNQ1OT1:TSS-DMR (also known as KvDMR1 or ICR2;
Lee et al., 1997; Caspary et al., 1998). This second DMR is
a CpG island within intron 10 of the Kcnq1/KCNQ1 gene
that inherits methylation from oocytes (Hiura et al., 2006)
and is the promoter for the long ncRNA KCNQ1OT1 (also
known as LIT1). In the mouse, this long ncRNA recruits the
histone methyltransferases G9a and EZH2 to the promoters
of the flanking genes depositing trimethylation of lysine 27
of histone H3 (H3K27me3) and H3K9me2 (Lewis et al.,
2004; Umlauf et al., 2004; Mohammad et al., 2012) on
the paternal allele bring about imprinting in the placenta
(Okae et al., 2012). Truncation of Kcnq1ot1 results in loss of
imprinted expression of all genes in the placenta, confirming
that the products of transcription are essential for imprinting
maintenance (Mancini-Dinardo et al., 2006). Interestingly,
despite conserved expression of KCNQ1OT1, imprinting of
the placenta-specific transcripts within the human orthologous
domain is not conserved, since their promoters are not decorated
with allelic repressive histone modifications (Monk et al., 2006)
(Figure 1A). However three genes, CDKN1C, PHLDA2, and
SLC22A18 are imprinted, being monoallelically expressed in both
placenta and fetal tissues (Yatsuki et al., 2002; Monk et al.,
2006).
The CDKN1C Gene
Cyclin-dependent kinase (CDK) Inhibitor 1C (also known as
p57Kip2) has four exons and was first discovered as a result
of sequence similarity with other CDK inhibitors in a two-
hybrid screening (Hatada and Mukai, 1995; Matsuoka et al.,
1995). CDKN1C mRNA transcripts are found in placenta, heart,
brain, lung, skeletal muscle, kidney, pancreas, and testis by
northern analysis (Matsuoka et al., 1995). Microarray expression
analysis reveals that CDKN1C is most abundant in placenta
compared to somatic tissues (Sood et al., 2006). The protein
has highly conserved N-terminal CDK inhibition and C-terminal
domains. The human protein, but not the mouse, also contains
a proliferating cell nuclear antigen (PCNA) binding domain
required for preventing DNA replication (Watanabe et al., 1998).
In addition CDKN1C has a QT-box involved in protein-protein
interactions and a unique proline-rich and acidic domain in the
mouse, replaced with proline–alanine (PAPA) repeats in humans,
which are involved in mitogen-activated protein kinase (MAPK)
phosphorylation (Lee et al., 1995). The absence of conserved
sequence in the mid-region of the protein could be attributable to
the lack of function, merely acting as a spacer region to separate
the functional N- and C-terminal domains (Matsuoka et al., 1995;
Tokino et al., 1996) (Figure 1B).
1http://www.imprinting-disorders.eu
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FIGURE 1 | Schematic representation shows the relative organization of genes, CpG islands and differentially methylated regions (DMRs) for
KCNQ1OT1-CDKN1C domain. (A) The centromeric imprinting domain on human chromosome 11p15.5 highlighting the role of the ncRNA KCNQ1OT1 in
recruiting the G9a and EZH2 histone methyltransferase complexes to the paternal allele of CDKN1C. Open boxes depict non-imprinted genes. Blue boxes are
paternally expressed genes; red boxes are maternally expressed genes, respectively. Lollipops signify CpG islands with open circles unmethylated and black circles
methylated. The arrows show the direction of transcription. (B) Structural features and functional domains of the CDKN1C gene and protein. The CDKN1C
possesses four exons with exons 2 and 3 encoding the functional protein. The protein has three key domains: a conserved amino-terminal containing the CDK
inhibitory domains; the proline–alanine repeat (PAPA) domain; and the proliferating cell nuclear antigen (PCNA) domain which contains a nuclear localization signal.
The nucleotide and amino acid sequence of the PCNA domain is shown.
CDKN1C Cell Cycle Function
CDKN1C is one of the CDKs inhibitors belonging to the Cip/Kip
family, which includes CDKN1A (p21cip1) and CDKN1B
(p27kip1). These proteins are required for cell cycle transition
and play important roles in coordinating cell proliferation,
differentiation and maintenance of the non-proliferative state
of cells. Cdkn1c is primarily expressed in cells that are exiting
cell cycle but are not terminally differentiated and shows
specificity for G1 CDKs. It can bind several CDKs in a cyclin-
dependent manner, including cyclin A/Cdk2, cyclin E/Cdk2,
cyclin E/Cdk3, cyclin D2/Cdk4 and, to a lesser extent, cyclin
D2/Cdk6. Furthermore, CDKN1C can inhibit the kinase activity
of the G1 cyclin Cdk2, Cdk3, and Cdk4 complexes. Therefore
CDKN1C is capable of inhibiting several CDK with demonstrated
roles in the G1/S-phase transition. However, in mouse embryonic
fibroblasts and placenta from null animals, disruption of the
protein does not affect the activities of Cdk2 and Cdk4 (Takahashi
et al., 2000), suggesting that Cdkn1c may have a biological
activity other than inhibition of Cdk activities, presumably linked
with PCNA-associated DNA replication regulation (Watanabe
et al., 1998), thus affecting cell cycle regulation via different
mechanisms.
Mutations of Human CDKN1C and Growth
In addition to large copy-number alterations of 11p15 that
lead to developmental phenotypes (Begemann et al., 2012;
Cerrato et al., 2014), mutations of CDKN1C also give rise to
growth abnormalities. Since CDKN1C functions as a negative
regulator of cellular proliferation, aberrations in this gene are
predicted to result in over-proliferation and predisposition to
cancer. Indeed, maternally inherited loss-of-function mutations
are associated with 5% of sporadic and 50% of familial cases of
Beckwith–Wiedemann syndrome (BWS; Lim and Maher, 2010;
Eggermann et al., 2014). These genetic alterations in BWS are
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rare compared to epimutations of the KCNQ1OT1:TSS-DMR
that results in overexpression of the KCNQ1OT1 ncRNA and
concomitant repression of both alleles of CDKN1C (Diaz-Meyer
et al., 2003).
Recent reports of maternally inherited gain-of-function point
mutations within the PCNA-binding domain are associated
with the growth restriction disorders IMAGe (Arboleda et al.,
2012) and Silver–Russell syndromes (SRS; Brioude et al., 2013).
This domain is required for PCNA-dependent and CRL4Cdt2-
mediated ubiquitination of three lysine residues, Lys278, Lys280,
and Lys286 (Kirchmaier, 2011), with mutations presumably
increasing the stability of the protein (Hamajima et al.,
2013). Interestingly, expression of IMAGe-associated CDKN1C
mutations does not interfere with the ability of CDKN1C to
inhibit the cell cycle in phase G0/G1 through binding of the
CDK, suggesting that domain-specific mutations have differential
effects on cell-cycle progression and developmental processes
(Arboleda et al., 2012).
CDKN1C and Placenta Development
During mid-to-late mouse placental development Cdkn1c is
expressed in giant trophoblast cells, glycogen cells within the
junctional zone and the syncytiotrophoblast (Westbury et al.,
2001; Tunster et al., 2011). Mice that express Cdkn1c at
twofold the normal endogenous level are growth restricted
from embryonic day E13.5, whereas mice deficient for Cdkn1c
were heavier at the same time point (Andrews et al., 2007).
Studying growth dynamics reveals that Cdkn1c mutant embryos
are ∼15% heavier than wild-type embryos at E15.5, 8% heavier
at E18.5, with the difference diminishing until it is no longer
apparent at birth (Tunster et al., 2011). Placentae of Cdkn1c
homozygotes and heterozygous mice inheriting a targeted
deletion from their mothers are larger than those of wild-
type mice. This enlargement was associated with prominent
proliferation of the labyrinthine and spongiotrophoblasts layers,
disordered vascularization and glycogen storage (Takahashi et al.,
2000) with substantial thrombotic lesions (Tunster et al., 2011).
The severe placental abnormalities observed in Cdkn1c mutant
mice preceded the attenuated overgrowth described previously.
This loss of growth potential late in gestation is a classic
indicator of placental insufficiency. Furthermore, the overgrowth
of mutant mice decreased in the face of increasing intrauterine
competition, suggesting that Cdkn1c is involved in the allocation
of the maternal resources via the placenta (Tunster et al.,
2011).
It is currently unknown if such dosage effects are observed in
humans, since the human placenta has a hemochorial structure
lacking a cell type equivalent to the giant trophoblast cell in
mice (Carter and Enders, 2004). Therefore the role of CDKN1C
in the human placenta might differ from that in the mouse.
Several small studies have investigated changes in CDKN1C
expression in human placenta cohorts with heterogeneous
clinical characteristics (healthy pregnancies, preeclampsia, small
for gestational age, and IUGR), with consistent up-regulation
observed in IUGR suggesting that deregulation of this genes
might play a role in prenatal growth (McMinn et al.,
2006; Cordeiro et al., 2014). To further clarify the role
of CDKN1C in fetal growth we have performed placental
expression and DNA methylation profiling in normal and
non-syndromic IUGR placental tissues. Combined interrogation
of publicly available CTCF ChIP-seq and ChIA-PET data
with molecular confirmation in placenta shows that CDKN1C
physically interacts with putative long-range enhancer regions
that we propose form constitutive chromatin loops and regulate
expression.
MATERIALS AND METHODS
The Placenta Cohort
Seventy-seven pregnant women delivering their babies in Sant
Joan de Déu Hospital, Barcelona, participated in the study,
contributing 89 newborns. The protocol was approved by both
the Sant Joan de Déu Hospital and IDIBELL Research and
Ethics Committees (PI35/07 and PR006/08) and individual
informed consent was obtained. Upon delivery, the placentae
were weighed and biopsies from the fetal side adjacent to
the umbilical cord insertion site were excised. The tissue
was thoroughly rinsed in saline and snap frozen in liquid
nitrogen. Maternal blood samples were collected in EDTA tubes
and frozen at –20◦C until processed. Clinical information on
pregnancy course for the anonymized samples was recorded.
For the purpose of the analysis, subgroups were established
according to the characteristics of the pregnancy and of the
newborn (term or preterm, IUGR or non-IUGR, conceived
spontaneously or by assisted reproduction). According to length
of gestation, newborns were classified in: term (≥37 weeks),
late and moderate preterm (>32 and <37 weeks) and very
preterm (≤32 weeks). IUGR was defined as a weight below
the third percentile for gestational age or below the 10th
percentile when accompanied by fetal Doppler flow abnormalities
(Tables 1–3).
Other Tissues and Cell Lines
Control lymphoblastoid cell lines were established by EBV
transformation of peripheral blood cells and propagated in
RPMI media supplemented with 10% fetal calf serum (FCS)
and antibiotics. The human TCL1 placental trophoblast cell line
was grown in Dulbecco’s modified Eagle’s medium supplemented
with 10% FCS and antibiotics. Prior to ChIP and 3C,
the cell line 11p15 methylation signatures were compared
to normal leukocytes and placenta samples to ensure that
the transformation process had not altered the epigenetic
profile.
Nucleic Acid Extraction
Genomic DNA from placenta samples was prepared by
SDS/Proteinase K lysis followed by phenol/chloroform extraction
and ethanol precipitation. DNA from blood and cell lines was
extracted using a commercial kit (QIAamp DNA Blood Midi
Kit R©, QIAGEN), following the manufacturer’s instructions. Total
RNA was extracted using Trizol R© (Invitrogen), and 1 µg of RNA
was treated with DNase (amplification grade DNase I, Invitrogen)
prior to RT. Reverse transcription was performed with MMLV
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retrotranscriptase (Promega) and random primers (Promega)
following the manufacturer’s instructions.
Genotyping PCR Reactions
Sequences were obtained for all DNA samples using PCR and
direct sequencing of the resulting amplicons using primers for the
PCNA domain of CDKN1C, the minimal promoter of CDKN1C
and the putative enhancer regions (see Supplementary Table
S1 for primer sequences). Approximately 200 ng genomic DNA
was amplified using BioTaq DNA Polymerase (Bioline). PCR
was performed for 35 cycles of denaturation at 94◦C for 30 s,
followed by 30 s annealing and extension at 72◦C for 60 s.
PCR amplicons were purified using ethanol precipitation and
TABLE 1 | Clinical characteristics of the newborns in the sample.
Newborn
characteristics
n (%) p-value
IUGR (n = 36) Control (n = 53)
Gender: boys 14 (38.9) 28 (52.8) 0.196
Gestational age group
(w = weeks)
Term (≥37 w) 13 (36.1) 21 (39.6)
Late preterm
(34 + 1 − 36 + 6 w)
11 (30.6) 7 (13.2) 0.226
Moderate premature
(32 + 1 − 34 w)
6 (16.7) 11 (20.8)
Very premature (≤32 w) 6 (16.7) 14 (26.4)
Multiple gestation 11 (30.6) 19 (35.8) 0.604
No previous gestation 21 (58.3) 36 (67.9) 0.355
Conception by ART 11 (30.6) 17 (32.1) 0.880
Preeclampsia 8 (22.2) 2 (3.8) 0.014∗
Labor 18 (50.0) 32 (60.4) 0.333
Delivery by cesarean
section
23 (63.9) 30 (56.6) 0.492
Mean ± SD
Gestational age (w) 35.1 ± 3.5 33.8 ± 7.3 0.274
Anthropometric data at
birth
Birth weight (g) 1841 ± 564 2340 ± 952 <0.003∗
Birth weight SDS −1.55 ± 0.68 0.22 ± 0.72 <0.0001∗
Length (cm) 43.0 ± 4.3 45.0 ± 6.2 0.123
Length SDS −1.26 ± 1.07 0.21 ± 0.68 <0.0001∗
Head circumference
(HC, cm)
30.4 ± 2.6 31.5 ± 4.3 0.190
HC SDS −1.22 ± 0.82 0.20 ± 0.76 <0.0001∗
Placental weight (g) 396 ± 133 578 ± 203 <0.0001∗
Birth weight to placenta
ratio
4.89 ± 1.20 4.25 ± 1.29 0.034∗
Standard deviation score (SDS), a variable that represent the distance of a data
point to the mean of the distribution as measured in SDs. Values are expressed as
number (n) and percentage and were compared between groups by Chi-square
tests. Continuous variables are summarized as mean ± standard deviation and
Student’s t-testing was used for statistical comparison. ∗P < 0.05 were considered
significant. Note, since there are methylation differences in the placenta that are
due to gestational age both IUGR and control patients were recruited amongst
term and preterm deliveries to minimize the difference between groups regarding
this parameter.
TABLE 2 | Maternal data.
Maternal characteristics n (%)
Ethnicity: Caucasian 55 (71.4)
Parity: primiparous 49 (63.6)
Assisted reproduction 19 (24.7)
Previous obstetric history
None 53 (68.8)
Infertility 12 (15.6)
Gestational hypertension/Pre-eclampsia 3 (3.9)
Recurrent miscarriage (≥3) 3 (3.9)
Previous IUGR 1 (1.3)
Other 2 (2.6)
Missing 3 (3.9)
Multiple gestation 19 (24.7)
Cesarean section 41 (53)
Pre-eclampsia 9 (11.7)
Pre-existing conditions
None 58 (75.3)
Chronic hypertension 5 (6.5)
Psychologic/psychiatric disorders 2 (2.6)
Gestational age group
Term (≥37 w) 34 (44.2)
Late preterm (34 + 1 − 36 + 6 w) 13 (16.9)
Moderate preterm (32 − 34 w) 14 (18.2)
Very preterm (≤32 w) 16 (20.8)
Mean ± SD
Age at delivery (years) 32.5 ± 6.0
Height (cm) 162.6 ± 7.1
Weight (kg)
Pre-pregnancy 64.9 ± 15.4
At delivery 76.7 ± 14.8
Gestational age at delivery (weeks) 35.0 ± 4.7
Quantitative values are expressed as number (n) and percentage. Continuous
variables are summarized as mean ± standard deviation.
subsequently sequenced with the BigDye Terminator reaction
kits on an ABI 3730 DNA analyser (PE Biosystems).
Quantitative Polymerase Chain Reaction
Expression of CDKN1C was analyzed by quantitative real-
time RT-PCR with a fluorochrome (SYBR R© Green) assay
and normalized against RPL19 (Iglesias-Platas et al., 2014).
This housekeeping gene was selected because of optimal
expression stability in placental tissue compared to other
commonly used housekeeping genes (Supplementary Table S2).
Primers were designed in different exons or across intron/exon
boundaries to avoid amplifying contaminating genomic DNA
(see Supplementary Table S1 for primer sequences). The assays
were run in triplicate in 384 well plates in a 7900HT Fast Real
Time PCR System (Applied Biosystems). Dissociation curves
were obtained at the end of each reaction to rule out the presence
of primer dimers or unexpected DNA species in the reaction.
Non-template controls, an interplate control and standard curves
from the same serial dilutions of cDNA obtained from pooled
normal placental tissue were included in each assay. Results were
analyzed with the SDS 2.3 software (Applied Biosystems). The
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TABLE 3 | Maternal data by study group.
Maternal
characteristics
n (%) p-value
IUGR (n = 34) Control (n = 43)
Ethnicity: Caucasian 27 (79.4) 28 (65.1) 0.489
Parity: primiparous 20 (58.8) 29 (67.4) 0.435
Assisted reproduction 9 (26.5) 10 (23.3) 0.794
Previous obstetric
history
11 (33.3) 10 (24.4) 0.396
Singleton gestation 9 (26.5) 10 (23.3) 0.745
Cesarean section 21 (61.8) 20 (46.5) 0.183
Labor 18 (52.9) 31 (27.9) 0.083
Pre-eclampsia 8 (23.5) 1 (2.3) 0.009∗
Healthy before
pregnancy
22 (68.8) 36 (87.8) 0.046∗
Chronic hypertension 4 (12.5) 1 (2.4) 0.161
Gestational age group
Term (≥37 w) 13 (38.2) 21 (48.8)
Late preterm
(34 + 1 − 36 + 6w)
11 (32.4) 2 (4.7)
Moderate preterm
(32 − 34 w)
5 (14.7) 9 (20.9)
Very preterm (≤32 w) 5 (14.7) 11 (25.6)
Age at delivery (years) 33.2 ± 6.3 32.0 ± 5.8 0.428
Height (cm) 162.1 ± 7.0 163.0 ± 7.3 0.621
Weight (kg)
Pre-pregnancy 63.0 ± 15.7 66.3 ± 15.2 0.390
At delivery 73.9 ± 15.2 79.0 ± 14.3 0.181
Gestational age at
delivery (weeks)
35.5 ± 3.6 34.6 ± 5.5 0.401
Mothers were classified in the IUGR group if any of the babies in the current
gestation fulfilled diagnostic criteria for IUGR. Quantitative values are expressed
as number (n) and percentage and were compared between groups by Chi-square
tests. Continuous variables are summarized as mean ± standard deviation and
Student’s t-testing was used for statistical comparison. ∗P < 0.05 were considered
significant.
DataAssist v2.0 R© software (Applied Biosystems) was used for
exclusion of outlier replicates and for interplate standardization
for comparisons. Only samples with two or more valid readings
per triplicate were included. Analysis of the results was performed
using the comparative 11CT (RQ) method (Schmitthen and
Livak, 2008).
Assessment of Imprinted Expression
Analysis of allelic expression was determined using PCR across
the polymorphic PAPA repeat in the second exon of CDKN1C
(see Supplementary Table S1 for primer sequences). The PCRs
were performed with Immolase Taq polymerase (Bioline) for
40 cycles with an annealing temperature of 60◦C. The resulting
PCR products were separated on a 4% agarose gel stained with
SYBR safe (Thermo Fisher Scientific). All placental DNA samples
were genotyped to identify heterozygous individuals. Expression
was then analyzed in heterozygous samples by RT-PCR with
imprinting confirmed if a single band was observed in the RT-
PCR product of a heterozygous sample. In these samples, the
parental origin of expression was determined, when possible,
by assessing the maternal genotype. In addition, RT-PCR was
performed on RT-positive and negative samples in order to rule
out genomic contamination.
Allele-Specific Bisulfite PCR
Approximately 1 µg DNA was subjected to sodium bisulfite
treatment and purified using the EZ GOLD methylation kit
(ZYMO, Orange, CA, USA) and ∼50 ng of converted DNA
used for all bisulfite PCR reactions. Bisulfite PCR primers for
each region were used with Immolase Taq polymerase (Bioline,
London, UK) at 45 cycles with an annealing temperature of
53◦C (see Supplementary Table S1 for primer sequences).
The resulting PCR product was cloned into pGEM-T easy
vector (Promega), transfected into JM109 bacteria and individual
colonies sequencing using standard T7 sequence primer.
Methylation Analysis by Bisulfite Pyrosequencing
Bisulfite treatment of 1 µg of DNA was performed with the
EZ Gold in a 96-well plate format (EZ-96 DNA Methylation-
GoldTM
R©
Kit, Zymo Research), following the manufacturer’s
protocol. A commercial control was used as reference for
bisulfite-converted fully methylated DNA (EpiTect Control
DNA R©, methylated, Qiagen). Pyrosequencing was selected
for the quantitative assessment of DNA methylation at the
KCNQ1OT1:TSS-DMR, the CDKN1C promoter and enhancer
regions using standard primers with the exception that the
reverse primer was biotin-labeled. Immobilization of the PCR
products for purification was achieved by streptavidin-coated
sepharose beads (Qiagen) with the use of the PyroMark Q96
Vacuum Prep Workstation R© and sequenced using a PyroMark
Q96 MD machine according to the manufacturer’s instructions.
Western Blot Analysis
Proteins from placenta samples with opposing CDKN1C
transcript abundance as determined by qRT-PCR were extracted
in standard lysis buffer (50 mM Tris 7.5 pH, 150 mM NaCl,
1 mM EDTA) containing 1% SDS with sonication to disrupt
genomic DNA. Twenty-five micrograms β-mercaptoethanol
denatured lysates were separated by PAGE gel electrophoresis
and blotted onto a nitrocellulose transfer membrane (Whatman,
Life Sciences). The membrane was blocked in 5% milk PBS-T and
immunoprobed with antibodies raised against CDKN1C (Abcam
anti-p57kip2: ab75974) and β-actin (Sigma: A1978). Washed
membranes were incubated with corresponding peroxidase-
conjugated secondary antibody. The immunoreactive proteins
were visualized using the Immobilon chemiluminescent HRP
substrate detection kit (Millipore). Bands were quantitated by
direct scanning of the western blot films and processed with
ImageJ software.
Chromatin Immunoprecipitation
One hundred micrograms of snap frozen placental tissue were
reduced to powder with a pestle and mortar under liquid
nitrogen. The pulverized placenta sample was cross-linked with
1% formaldehyde for 7 min at room temperature and the
reaction blocked by adding glycine to a final concentration of
0.125 M. Similar cross-linking protocols were used for ∼80
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million lymphoblastoid cells. Approximately 100 µg chromatin
were used for each immunoprecipitation reaction with Protein
G magnetic beads (Millipore, 16–157) and an antibody raised
against CTCF (Millipore, 07–729). For each ChIP, a fraction of the
input chromatin (5%) was also processed for DNA purification
and a mock immunoprecipitation with a neutral, unrelated IgG
(Millipore PP64B Lot: 1968270) antiserum was carried out in
parallel. The levels of immunoprecipitated chromatin at specific
regions were determined by standard PCR (see Supplementary
Table S1 for primer sequences).
3C Analysis
The chromatin conformation capture (3C) protocol was
performed as previously described (Court et al., 2014a; Iglesias-
Platas et al., 2014). Briefly, HindIII was used to digest 1 × 107
formaldehyde cross-linked nuclei from the placental cell line
TCL1 (overnight digestion, 1200 U, NEB). Following efficiency
restricted enzyme digestion the chromatin was ligated overnight
in a 500 µl reaction volume using 1950 units of T4 ligase
(Fermentas). DNA was decross-linked by incubating overnight
at 65◦C and purified using phenol/chloroform extraction. This
DNA was used for PCR to determine long-range chromatin
interactions, using constant primers in the unmethylated
CDKN1C gene body CpG island (see Supplementary Table
S1 for primer sequences). Primer efficiency was determined
using digested and ligated BAC DNA. All 3C experiments were
performed in two technical replicates.
Statistical Analysis
Clinical and molecular data were introduced in a Statistical
Package for Social Sciences (SPSS R©, IBM) software v17.0
database. Expression levels were expressed in logarithmic
scale in order to achieve a variable distribution closer to
normality and subsequently analyzed against clinical values.
Continuous variable are summarized throughout the manuscript
as mean ± standard deviation (SD) and qualitative variables
as number and percentage. Comparisons between groups were
evaluated with chi-square for categorical variables and t-Student
test (for two groups, 2-tailed analysis) or ANOVA (more than
two groups) for continuous variables. Non-parametric tests were
applied where indicated. Relationships between variables were
explored by Pearson’s correlation and subsequently introduced
in multiple regression models to adjust for possible interactions
or confounding factors. Results were considered significant if
the p-value was under 0.05. This study was sufficiently powered
to detect differences in expression of 0.7 SDs between groups
(statistical power 80%) and correlations with a Pearson’s r
coefficient greater than 0.3 between gene expression and clinical
variables (statistical power 86%).
RESULTS
Cohort Description
Eighty-nine placental samples were obtained from 77
pregnancies. The samples corresponded to 15 twin pregnancies
(both newborns analyzed in eight sets and only one in the other
seven) and two triplet pregnancies contributing six newborns to
the study.
Most mothers (71.4%) were of Caucasian origin and were
healthy before pregnancy. Characteristics of the case and the
control groups are summarized in Tables 1–3. Due to the
high-risk obstetric characteristics of our population (IUGR,
prematurity, complications of pregnancy), there was a high rate
of cesarean section (53%).
Thirty-six of the fetuses were diagnosed with IUGR during
pregnancy. Mothers of IUGR babies had a higher prevalence
of preeclampsia (23.5% vs. 2.3%, Chi-square p = 0.01) or
chronic hypertension. There were no differences regarding
primiparity (58.3% vs. 67.9%, Chi-square p = 0.35), delivery
by cesarean section (63.9% vs. 56.6%, Chi-square p = 0.49)
or in the percentage of mothers undergoing labor (50.0% vs.
60.4%, Chi-square p= 0.33) between IUGR and normally grown
gestations. Conception by ART was equally frequent in both
groups (30.6% vs. 32.1%, Chi square p = 0.88). IUGR and
normally grown fetuses were comparable in their remaining
clinical characteristics except, by definition, size for gestational
age at birth (Student’s t p< 0.001) and the incidence of detection
of Doppler flow abnormalities (Chi-square p< 0.001).
Increased Levels of CDKN1C in IUGR
Placentae
Expression levels of CDKN1C relative to the endogenous RPL19
gene were 1.4 times higher in the IUGR group in a univariate
analysis (IUGR RQ 0.77± 0.09 vs. controls 0.56± 0.06, Students’
t p = 0.04) (Figure 2A). For a better fitting in statistical
analysis, RQ was transformed by Log10, rendering a distribution
closer to normality. We found no correlation between CDKN1C
and maternal age, height or weight or with gestational age
or anthropometric parameters of the baby, suggesting that the
relationship between expression and growth is specific to an effect
of IUGR rather than based on birth weight (a full list of non-
significant variables can be found in Supplementary Table S3).
Expression of CDKN1C was also found to be decreased in the
placenta of primiparous women (log10 CDKN1C−1.40 ± 0.33
in primiparous vs. −1.14 ± 0.28 in multiparous, p < 0.001)
and in gestations conceived by assisted reproduction (log10
CDKN1C−1.47 ± 0.35 in TRA vs. −1.22 ± 0.30 in spontaneous
conceptions, p < 0.001). There were no differences by gender
of the fetus, presence of labor, complication by pre-eclampsia,
maternal smoking habits or between singleton and multiple
pregnancies.
Multivariate analysis by direct logistic regression (dependent
variable: IUGR yes/no) was performed to rule out the effect of
confounding variables with an effect on CDKN1C expression
in our sample (primiparity and ART); we also included pre-
eclampsia as a covariate, as it was the only clinical feature
with a different prevalence between the IUGR and control
groups (prevalence of 22.2% vs. 3.8%, Chi-square test p = 0.01).
Primiparity and ART were finally excluded from the model,
as they did not have a statistically significant contribution.
The final statistical model (Nagelkerke R2 0.172, p = 0.002)
included expression of CDKN1C and presence of preeclampsia.
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FIGURE 2 | Scatter plots representing RQ (relative quantification) values of CDKN1C transcripts and proteins. (A) A graph showing the transcript
abundance of CDKN1C in IUGR and control placenta samples with the line representing the median. (B) The expression profile in ART and spontaneously conceived
samples. (C) Quantification of protein expression differences in lowly and highly transcribed placenta samples. (D) An example of a western blot used for protein
quantification.
The effect of each of these variables on IUGR was significant
[Log10 CDKN1C expression, Exp (B) 4.91, 95% CI 1.09–22.10,
p = 0.038; preeclampsia, Exp (B) 5.78, 95% CI 1.12–29.73,
p= 0.05], indicating an independent effect of each of these factors
on IUGR.
Western blot analysis revealed that extreme mRNA levels
of CDKN1C were also observed at the protein level with
higher levels detected in IUGR placentae (Figures 2C,D).
However, the difference at the protein level is smaller suggesting
there is post-transcriptional regulation of CDKN1C in human
placenta.
Expression Differences in ART Placenta Biopsies
Altered levels of expression of imprinted genes have been
reported in both mouse and human placentas after the use
of assisted reproductive technologies (ART; Katari et al., 2009;
Iglesias-Platas et al., 2014) and placental epigenetic profiles seem
particularly vulnerable (Fortier et al., 2008). Levels of expression
of CDKN1C were lower in placentas of babies conceived by ART
(Figure 2B). In our sample, mothers in the ART group were
significantly older (35.5 ± 6.3 vs. 31.9 ± 5.8 years, Student’s t
p = 0.01) and taller (166.7 ± 6.4 vs. 162.0 ± 7.2 cm, Student’s
t p = 0.01), more likely to be primiparous (89.3% vs. 52.5%,
Chi square p = 0.001), to carry a multiple pregnancy (78.6% vs.
16.4%, Chi square p < 0.001) and to be delivered by elective
cesarean section, without having undergone labor (67.9% vs.
32.8%, Chi square p = 0.02). Gestational age at birth was
lower in the ART group (32.4 ± 7.5 vs. 35.4 ± 4.8 weeks,
Student’s t p = 0.04) and baby size was concordantly smaller,
but there were no differences regarding anthropometry for
gestational age. The groups were similar regarding gender of
the newborn and incidence of IUGR and pre-eclampsia. To
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further explore the relationship between ART, expression of
CDKN1C and the aforementioned clinical variables, we used
hierarchical multiple regression, controlling for the identified
confounders. The model including ART, maternal age and
height, primiparity, labor and multiple gestation was borderline
significant (adjusted R2 0.112, p= 0.05) and ART and multiparity
were the only statistically significant contributors to the variance
of CDKN1C levels. A linear regression model for the variance
of CDKN1C expression including only ART and primiparity
had an adjusted R2 of 0.174 (p < 0.001), with both clinical
values having a significant contribution (ART standardized
β = 0.249, p = 0.01, primiparity standardized β = 0.284,
p= 0.01).
Increased Expression in IUGR Despite Maintained
Imprinted Expression
To ensure that CDKN1C maintained monoallelic expression,
with transcription solely from the maternal allele, we determined
the allelic origin of transcription in all heterozygous individuals.
In total 10 samples were heterozygous for the PAPA repeat
in exon 2. This represented all groups of gestational age,
intrauterine growth and mode of conception. Monoallelic
expression was observed in all cases (Figure 3), and origin
was confirmed as maternal in three cases with homozygous
mothers.
Normal Methylation of CDKN1C in IUGR
Placental Samples
To determine if the differences in expression observed in IUGR
and following ART is due to changes in DNA methylation at the
CDKN1C promoter we performed pyrosequencing to quantify
methylation levels. The bisulfite PCR product incorporated
31 CpG dinucleotides within the amplicon (Figure 4A), with
the subsequent pyrosequencing analysis limited to six CpG
dinucleotides due to sequence restrictions for the internal
sequence primer and the limited length of the sequence reads.
The arithmetic mean of the six CpG dinucleotides was used as
a representative measure of the level of methylation for each
placenta sample in our cohort. Pyrosequencing did not detect any
differences in methylation between control and IUGR placentae
(mean methylation 12.55 ± 0.53% in controls vs. 12.13 ± 0.79%
in IUGR, Student’s t p = 0.65; Figure 4B) or between ART
and spontaneously conceived pregnancies (mean methylation
11.21 ± 0.60% in ART vs. 12.86 ± 0.56% in spontaneous,
Student’s t p= 0.09).
Since the maternal expression of CDKN1C is regulated in-cis
by the KCNQ1OT1:TSS-DMR we also quantified the methylation
of this region by pyrosequencing. We observed no deviation
from the expected ∼50% methylation in any sample. This
suggests that methylation defects at this imprinted DMR are not
responsible for the variation in expression levels (Figures 4C,D).
This is in agreement with other studies that have shown that
changes in imprinted gene abundance in placenta samples are not
attributable to methylation defects (Ishida et al., 2012; Iglesias-
Platas et al., 2014).
No Evidence for Genetic Variability
Influencing CDKN1C Expression
Since the increased expression of CDKN1C in IUGR babies
occurs without loss of imprinting, we hypothesized that
underlying genetic variants may influence expression in a similar
manner as previously reported for the nearby imprinted gene
PHLDA2 (Ishida et al., 2012). We sequenced ∼1.2 kb upstream
from the transcription start site, overlapping the promoter CpG
island in two PCR products to identify polymorphisms. The
UCSC genome browser (Build GRCh37/hg19) listed five SNPs in
this region found in>1% of samples, encompassing rs116430081
to rs431222. However, upon sequence analysis all SNPs were
identified in control and IUGR samples with similar frequencies
as reported in dbSNP database2 (Table 4).
Identifying Long-Range Enhancer
Elements for CDKN1C
Both mouse transgenic studies and data obtained from rare
patients with deletions/duplications have suggested that cis-
acting regulatory elements are required for Cdkn1c/CDKN1C
expression, with murine placenta-specific enhancer(s) located
>315 kb from the gene (John et al., 2001). Recently, a
bioinformatics search for conserved non-coding regions
harboring the constitutive enhancer histone signature of
H3K4me1, H3K27ac, and DNAse1 hypersensitivity sites
(Heintzman et al., 2007; Creyghton et al., 2010; Encode Project
Consortium, 2012) revealed three likely candidate regions
(Cerrato et al., 2014) (Figure 5A). To identify potential CDKN1C
2http://www.ncbi.nlm.nih.gov/snp
FIGURE 3 | Allele specific expression of the CDKN1C gene in placenta biopsies. The first lane for each sample represents amplification of the PAPA repeat in
genomic DNA. PCR products were visualized on 4% agarose gels and alleles discriminated based on amplicon size. Only heterozygous genotypes were selected for
allelic expression analysis. The second lane is amplification from cDNA following reverse transcription showing monoallelic expression.
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FIGURE 4 | The methylation profiles of the CDKN1C promoter and KCNQ1OT1:TSS-DMR. (A) The left panels show an example of the placental and
leukocyte methylation profiles of the 31 CpG dinucleotides analyzed within the CDKN1C promoter CpG island as determined by cloning and direct sequencing.
(B) The methylation profiles, representing the average methylation of the six CpGs assayed by pyrosequencing within the CDKN1C promoter. (C) The bisulfite PCR
profiling for the 22 CpG dinucleotides analyzed in the KCNQ1OT1:TSS-DMR and (D) the resulting methylation profile as determined by pyrosequencing. Each circle
represents a CpG on the strand, and filled circles and open circles indicate methylated and unmethylated sites, respectively. Horizontal lines indicate the CpG sites
analyzed by pyrosequencing. PL, placenta; LY, lymphocyte.
enhancers in the human placenta we performed a bioinformatics
search for co-localization of H3K4me1 and H3K27ac peaks
in datasets generated from fetal placenta tissue available in
the GEO data repository (GSM110284; GSM1102795). The
ChIP-seq peaks were visualized using the UCSC genome browser
ENCODE analysis Hub option. This analysis identified the same
three intervals described by Cerrato et al. (2014) using ENCODE
ChIP-seq data generated in somatic tissues and cell lines.
Evidence for CTCF Mediated Chromatin
Looping between Enhancers and
CDKN1C
Recent studies have revealed that CTCF occupancy mediates
intra- and interchromosomal contacts (Holwerda and de Laat,
2013). Several canonical CTCF binding sites within the CDKN1C
gene body and proposed enhancer regions were identified using
an in silico analysis of ENCODE datasets in multiple tissues
(Figure 5A). To confirm in vitro binding we performed ChIP
with CTCF antisera on normal lymphoblast cells and placenta
(Figure 5B). The efficiency of the ChIP was confirmed by
precipitation of the H19/IGF2:IG-DMR and no enrichment
of the KCNQ1OT1:TSS-DMR. Subsequent analysis revealed
precipitation of CDKN1C and enhancer 3 in both cell types, but
not at enhancers 1 and 2, respectively.
Having confirmed CTCF binding at discrete locations within
the CDKN1C locus we hypothesize that CTCF dimerization
may orchestrate higher order chromatin loops (Rao et al., 2014;
de Wit et al., 2015). Next, we interrogated publically available
genome-wide ChIA-PET datasets which revealed that the CTCF
site within the CDKN1C gene body physically interacts with
the CTCF site with enhancer 3 located ∼360 kb away in
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TABLE 4 | SNP reference numbers, genetic variants, and population frequencies listed according to NCBI dbSNP database.
SNP ID Controls IUGR dbSNP 142
Enhancer 3 rs11823023 G: 84% A: 16% G: 81% A: 19% G: 85% A: 15%
rs179432 A: 77% G: 23% A: 76% G: 24% A: 70% G: 30%
rs179433 C: 77% T: 23% C: 76% T: 24% C: 70% T: 30%
rs179434 A: 68% C: 32% A: 67% C: 33% A: 57% C: 43%
rs179435 A: 78% G: 22% A: 76% G: 24% A: 67% G: 33%
rs179436 G: 84% A: 16% G: 82% A: 18% G: 83% A: 17%
Enhancer 2 rs2237884 T: 74% C: 26% T: 73% C: 27% T: 67% C: 33%
rs233434 G: 91% A: 9% G: 86% A: 14% G: 92% A: 8%
rs5789271 −: 56% G: 44% −: 60% G: 40% −:57 % G: 43%
rs12794000 C: 82% T: 18% C: 84% T: 16% C: 84% T: 16%
Enhancer 1 rs202159835 −: 94% +: 6% −: 88% +: 13% −: 99% +: 1%
rs233451 G: 78% A: 22% G: 77% A: 23% G: 83% A: 17%
rs163184 C: 58% T: 42% T: 71% T: 29% C: 63% T: 37%
Promoter rs431222 C: 71% T: 29% C: 72% T: 28% C: 79% T: 21%
rs452338 G: 71% T: 29% G: 72% T: 28% G: 79% T: 21%
rs34738237 −: 66% CA: 34% −: 74% CA: 26% −: 74% CA: 26%
rs116430081 C: 100% T: 0% C: 99% T: 1% C: 99% T: 1%
The frequency of observed genetic variants in our cohort classified as control or IUGR.
both breast (MCF7) and blood (K562) cell lines, indicative
of a constitutive chromatin loop (Figure 5A). To confirm
this physical interaction we performed chromatin conformation
capture experiments (3C) to identify potential chromatin folding.
3C-PCR assays were performed on the placental TCL1 cell line
and interaction frequencies were determined between a constant
HindIII site located near the CTCF binding site within CDKN1C
and other HindIII sites throughout the locus. We identified
strong interaction between the CDKN1C constant fragment with
the CTCF site in the enhancer region 3 (Figure 5C). Direct
sequencing of the PCR product revealed that the appropriate
chimeric products result from the 3C ligations (Figure 5D).
Unfortunately no informative SNPs were identified within the
vicinity of the HindIII sites associated with these loops that would
allow us to determine the parental origin of the resulting chemical
products. These results suggest that the CDKN1C expression,
at least in placenta, is dependent upon the active enhancer
configuration and higher-order chromatin looping.
Determining Genetic and Methylation
Variation at Enhancers
Having identified the putative enhancer regions that may
influence the expression of CDKN1C, we addressed if epigenetic
or genetic variation within these regions were associated with
IUGR in our samples. We optimized bisulfite pyrosequencing to
quantify DNA methylation of multiple CpG dinucleotides within
the enhancer regions. The CTCF sites associated with the long-
range enhancer 3 are unmethylated in all control samples and we
failed to detect any methylation changes with the IUGR profiles
being within the control methylation ranges (mean methylation
7.75% ± 0.23% in controls and 7.83% ± 0.26% in IUGR,
Student’s t p = 0.81). Similarly, despite tissue-specific differences
observed between placenta and leukocytes, we failed to identify
methylation changes at enhancer 1 associated with IUGR (mean
methylation 13.15% ± 0.46% in controls and 12.2% ± 0.84% in
IUGR, Student’s t p = 0.28). However, a small, but statistically
significant difference between normal and IUGR placentas was
observed at enhancer 2 (mean methylation 64.53% ± 0.92% in
controls and 69.48% ± 0.77% in IUGR, Student’s t p < 0.001;
Figure 6). Furthermore, genotype analysis of polymorphisms
within the enhancer regions failed to reveal any haplotypes
enriched in the IUGR group (Table 4). This suggests that large
variation within the enhancer intervals do not account for the
difference in CDKN1C expression observed in IUGR.
DISCUSSION
Much of the epigenetic research associated with IUGR has
focused on imprinted loci since they are critical for early growth
and metabolic adaptation; however, most data, including our
previous studies (Camprubí et al., 2013; Iglesias-Platas et al.,
2014), have revealed that methylation fluctuates very little at these
loci. This is presumably due to the fact that most imprinted
DMRs are associated with multiple layers of epigenetic regulation
(McEwen and Ferguson-Smith, 2010) that tightly maintain gene
expression in the face of any environmental perturbation like
maternal undernutrition (Radford et al., 2012). In future studies
it would be interesting to determine if changes in histone-tail
modifications, including lysine methylation, influence expression
in samples with normal DNA methylation.
The data presented in this study highlights the role of the
imprinted CDKN1C transcript in fetal growth via a placenta-
mediated mechanism. We have shown increased CDKN1C
expression in IUGR placentas after adjustment for other variables
influencing size at birth. The precise mechanism of action of
CDKN1C in the human placenta is unknown, but is likely to
involve regulation of the cell cycle. It would be interesting
to determine if the aberrant growth associated with higher
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FIGURE 5 | Chromatin conformation capture (3C) interaction across the 440 kb KCNQ1-CDKN1C region in human placenta. (A) Map of
KCNQ1OT1-CDKN1C domain showing location of three putative enhancer regions in multiple cell types defined by overlapping H3K4me1 and H3K27ac ChIP-seq
peaks and the relative position of transcripts, promoter and DMRs. The same intervals also show the canonical histone enhancer signature in first trimester placenta
ChIP-seq datasets. ChIA-PET color coding represents signal enrichment based on aligned reads; Black for high frequency interactions, gray for medium intensity
interactions. The positions of CTCF sites and HindIII sites utilized for 3C analysis are shown. (B) CTCF ChIP performed in placenta and lymphoblastoid cells. Input
chromatin was used as a positive control (input 5%). ChIP-recovered DNA, analyzed using PCR and the resulting amplicons visualized using agarose gel
electrophoresis. (C) All 3C PCR products were sized and visualized on a 2% agarose gels. The upper panel depicts the 3C PCR control in HindIII digested and
ligated BAC control DNA. Each target primer combination was analyzed with the reverse primer of the constant region mapping to a HindIII site within the CDKN1C
gene. The lower panel shows the 3C analysis performed on DNA-derived from cross-linked, digested and ligated chromatin from the placenta cell line TCL1. 3C
PCR products of correct size were observed for the enhancer 3 interaction. (D) Sequence analysis reveals the appropriate ligation products following 3C PCR
depicting higher-order chromatin contact between the CDKN1C constant fragment and the enhancer 3 region.
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FIGURE 6 | Methylation at the three putative CDKN1C enhancer regions. (A,C,E) The figures represent bisulfite PCR and sequencing for placenta and
leukocytes samples where each row corresponds to an individual sequenced DNA clone. Each circle represents a CpG on the strand, and filled circles and open
circles indicate methylated and unmethylated sites, respectively. Horizontal lines indicate the CpG sites analyzed by pyrosequencing. (B,D,F) The methylation
profiles, representing the average methylation of assayed CpGs as determined by pyrosequencing in IUGR and control control placenta samples. PL, placenta; LY,
lymphocyte.
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expression levels of CDKN1C continues following delivery, or
if there is catch-up growth indicative of placenta dysfunction.
Constitutional growth restriction associated with both IMAGe
syndrome and SRS have been reported in rare patients with
gain-of-function mutations in the CDKN1C PCNA domain that
presumably alters protein clearance by the ubiquitin-proteasome.
Whilst, we do not see mutations of this domain in non-
syndromic IUGR (data not shown), we do observe increased
protein abundance in IUGR placenta samples. Interestingly the
magnitude of increased mRNA expression and protein levels
differs greatly, suggesting there is extensive post-transcriptional
regulation of CKDN1C. Recently, the microRNA miR-221
has been shown to regulate CDKN1C mRNA levels (Sun
et al., 2011) and this specific miRNA has been shown to
be plentiful in third trimester/term placentas (Gu et al.,
2013).
Imprinted gene expression in the placenta can be influenced
by many factors including differences in the sampling site,
mode of delivery (Janssen et al., 2015), fetal sex (Iglesias-
Platas et al., 2014), and gestational age (Demetriou et al.,
2014). Regional variation in the expression of PHLDA2 has
previously been reported with modest elevation of expression
in samples taken at the distal edge of the placenta compared
to the ones near the cord insertion site (Janssen et al., 2015)
which may partially be attributed to differences in placental
architecture and blood supply. To overcome this we routinely
obtained biopsies from the same location on the fetal side of
the placenta within 2 cm of the cord insertion. In addition the
same authors observed elevated CDKN1C expression in placenta
from labored deliveries compared with elective cesarean sections.
We do not observe any differences in our larger cohort of
samples.
Furthermore difference in expression have can also be
modulated by gestational age, with the transcript levels of
the PHLDA2 gene showing an association with birth weight
(although not IUGR) in term samples (Apostolidou et al.,
2007; Ishida et al., 2012) but not in first trimester chorionic
villus sampling (Demetriou et al., 2014). Similar gestational age
associations have also been observed for additional imprinted
genes, including GRB10 in first trimester placenta samples and
IGF2 in a series of normal term biopsies (Moore et al., 2015)
but it has not been established if differences occur in biopsies
from complicated pregnancies. Interestingly different studies
have reported conflicting results for CDKN1C influencing fetal
size with three reports describing a negative correlation with
birth weight (McMinn et al., 2006; Moore et al., 2015; Piyasena
et al., 2015). It will be important to verify if changes in imprinted
gene expression are a direct cause of pregnancy complications, or
alternatively, they may reflect a common adaptive compensatory
mechanism in the placenta.
The increased abundance of CDKN1C, we observe in
IUGR placentas was not paralleled by changes in methylation
at the CDKN1C promoter or KCNQ1OT1:TSS-DMR. Other
authors have also found expression levels differences in
imprinted genes without obvious methylation changes in
the corresponding imprinted DMRs. This presumably reflects
transcriptional deregulation by other trans-acting mechanisms,
such as transcription factor binding (McMinn et al., 2006; Ishida
et al., 2012; Cordeiro et al., 2014; Iglesias-Platas et al., 2014;
Piyasena et al., 2015). We have previously shown that the
expression levels of PLAGL1 correlated with CDKN1C levels,
with PLAGL1 presumably exerting its influence as a zinc finger
transcription factor (Iglesias-Platas et al., 2014). However, the
precise location of the binding sites are unknown since the
long-range enhancer elements have yet to be characterized.
Recently a bioinformatics screen for somatic enhancers identified
three candidate regions (Cerrato et al., 2014) that are the
same as we identified in placenta. Experiments performed
by John et al. (2001) using BAC transgenes indicate that,
in addition to the DMR within the promoter of Kcnq1ot1,
expression of Cdkn1c requires interaction with a distant tissue-
specific enhancer located within the Kcnq1 gene. Using such
an approach, the enhancers for expression in the placenta were
not identified, suggesting they might be located more than
315 kb from Cdkn1c. This is consistent with our observation
as one of the putative enhancers we identify (region 3) maps
∼360 kb from CDKN1C and we show they physically interact in
placenta.
We have previously demonstrated that the imprinted
domains associated with PLAGL1 (Iglesias-Platas et al., 2014)
and PEG13/KCNK9 (Court et al., 2014a) require additional
transcription factors or active enhancers to facilitate imprinted
transcription from constitutive CTCF-mediated chromatin loops
that are stable and independent of transcription. Similarly the
data we present here suggest that CTCF orchestrates biallelic
higher-order chromatin interactions within the KCNQ1-domain
since the binding sites for CTCF, a known methylation-sensitive
DNA binding protein responsible for the looping, are all
unmethylated. Interestingly, we do not observe CTCF binding
within the KCNQ1OT1:TSS-DMR, suggesting that this interval
does not act as a methylation-sensitive insulator as has been
observed in mice (Du et al., 2003; Shin et al., 2008). However,
prominent CTCF binding was observed 5 kb downstream of the
DMR in most tissues analyzed by ENCODE. We hypothesize that
the level of CDKN1C transcription is regulated by a combination
of the shared enhancers and endogenous promoter sequences,
with the latter conferring the allelic specificity due to the
accumulation of repressive histone modification on the paternal
allele (Monk et al., 2006).
CONCLUSION
Our results show DNA methylation independent differences
of CDKN1C expression in placenta in non-syndromic IUGR
and between pregnancies of primiparous versus multiparous
mothers and gestations conceived spontaneously or by assisted
reproduction. Our results support the idea that distant enhancers
physically interact via long-range chromatin looping which in
turn regulate CDKN1C expression. Deciphering the role of
these putative enhancer elements in regulating tissue-specific
expression of CDKN1C will be important to understand the
molecular etiologies of non-syndromic IUGR, SRS, BWS, and
IMAGe syndrome.
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